Jos van Pelt

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 8

Top Topics

Ejection Fraction

Epithelial Mesenchymal Transition

Signaling Pathway

Top Venues

Journal of translational medicine

OncoTargets and therapy

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Jos van Pelt, Bob Meeusen, Rita Derua, Liesbeth Guffens, Eric Van Cutsem, Veerle Janssens, Chris Verslype
Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality. Journal of translational medicine 21 (1) (2023)
Jos van Pelt, Bob Meeusen, Rita Derua, Liesbeth Guffens, Eric Van Cutsem, Veerle Janssens, Chris Verslype
Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality. Journal of translational medicine 21 (1) (2023)
Jos van Pelt, Bob Meeusen, Rita Derua, Liesbeth Guffens, Eric Van Cutsem, Veerle Janssens, Chris Verslype
Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality. Journal of translational medicine 21 (1) (2023)
Jos van Pelt, Bob Meeusen, Rita Derua, Liesbeth Guffens, Eric Van Cutsem, Veerle Janssens, Chris Verslype
Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality. Journal of translational medicine 21 (1) (2023)
Carolina Méndez-Blanco, Flavia Fondevila, Paula Fernández-Palanca, Andrés García-Palomo, Jos van Pelt, Chris Verslype, Javier Gonzalez-Gallego, José Luis Mauriz
Correction: Méndez-Blanco et al. Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells. Cancers 2019, 11 , 1984. Cancers 15 (23) (2023)
Jos van Pelt, Bob Meeusen, Rita Derua, Liesbeth Guffens, Eric Van Cutsem, Veerle Janssens, Chris Verslype
Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality. Journal of translational medicine 21 (1) (2023)
Flavia Fondevila, Carolina Méndez-Blanco, Paula Fernández-Palanca, Tania Payo-Serafín, Jos van Pelt, Chris Verslype, Javier Gonzalez-Gallego, José Luis Mauriz
Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib. International journal of molecular sciences 22 (21) (2021)
Ashenafi Bulle, Jeroen Dekervel, Lise Deschuttere, David Nittner, Eric Van Cutsem, Chris Verslype, Jos van Pelt
Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts. OncoTargets and therapy 13 (2020)